Health Care [ 4/12 ] | Pharmaceuticals [ 10/74 ]
NASDAQ | Common Stock
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases.
The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease.
It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.
In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease.
Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 5, 25 | -0.39 Increased by +37.10% | -0.69 Increased by +43.48% |
| Feb 28, 25 | -0.41 Increased by +48.10% | -0.55 Increased by +24.87% |
| Nov 4, 24 | -0.50 Increased by +45.65% | -0.52 Increased by +3.85% |
| Aug 9, 24 | -0.45 Increased by +50.55% | -0.57 Increased by +21.64% |
| May 9, 24 | -0.62 Increased by +8.82% | -0.69 Increased by +10.14% |
| Feb 27, 24 | -0.79 Decreased by -27.42% | -0.90 Increased by +12.22% |
| Nov 9, 23 | -0.92 Decreased by -55.93% | -0.90 Decreased by -2.22% |
| Aug 10, 23 | -0.91 Decreased by -133.33% | -0.71 Decreased by -28.17% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -27.44 M Increased by +28.86% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -29.35 M Increased by +37.22% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -35.25 M Increased by +34.76% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -31.95 M Increased by +40.00% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -38.57 M Decreased by -9.24% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 1.08 M Increased by +N/A% | -46.75 M Decreased by -33.34% | Decreased by -4.35 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -54.03 M Decreased by -83.12% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -53.25 M Decreased by -166.02% | Decreased by N/A% Decreased by N/A% |